뒤로
MoonLake Immunotherapeutics(MLTX) 가격
MLTX 주가 차트
MLTX 수입
MoonLake Immunotherapeutics
$16.27
-2.92%
$-0.49
오늘 기준:Jan 20, 16:47:23 GMT-5
최신 수익 결과: Q3 '25
보고됨: 2025-11-05
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
MLTX의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
MoonLake Immunotherapeutics MLTX의 지난 분기 매출 실적은 어땠나요?
MoonLake Immunotherapeutics의 매출 추정치는 얼마인가요?
MoonLake Immunotherapeutics의 수익 품질 점수는 얼마인가요?
MoonLake Immunotherapeutics는 언제 수익을 보고하나요?
MoonLake Immunotherapeutics의 예상 수익은 얼마인가요?
MoonLake Immunotherapeutics은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$16.76
시가
$16.5
일일 범위
$16.16 - $17
52주 범위
$5.95 - $62.75
거래량
2.1M
평균 거래량
4.5M
EPS(TTM)
-3.33
배당수익률
--
시가총액
$1.1B
MLTX란 무엇인가요?
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 100 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.